**Zwitterionic Chitosan Derivative, a New Biocompatible Pharmaceutical Excipient, Prevents Endotoxin-mediated Cytokine Release.**

Gaurav Bajaj1, William G Van Alstine2, Yoon Yeo1,3, \*

**Table S1.** Chitosans used in this study and relevant properties

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Description | Molecular weight | Degree of deacetylation (primary amine content) | Aqueous solubility at pH 7.4 |
| Chitosan glutamate | Glutamate salt form | 200 kDaa | 75–90% | Insoluble |
| Glycol chitosan | 2-hydroxyethylether derivative of chitosan | 82 kDaa | 83% | Soluble |
| LMCS | Parent of ZWC | 15 kDaa | 87% | Insoluble |
| ZWC (An/Am=0.3) | <29%b | ~15 kDa | >58% | Soluble |
| ZWC (An/Am=0.7) | >52%b | ~15 kDa | <35% | Soluble |

1. Provided by the manufacturer.
2. Estimated from the previous study [[22](#_ENREF_22)].